{
    "organizations": [],
    "uuid": "b4667b61e07fb11f5ee09f55aef9e1a9cb05ddfe",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunovaccine-and-incyte-expand-cl/brief-immunovaccine-and-incyte-expand-clinical-collaboration-idUSFWN1S10NQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Immunovaccine Inc:\n* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER\n* IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTEâ€™S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE\n* IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL\n* IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-24T19:12:00.000+03:00",
    "crawled": "2018-04-25T14:32:11.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "immunovaccine",
        "inc",
        "immunovaccine",
        "incyte",
        "expand",
        "clinical",
        "collaboration",
        "evaluating",
        "combination",
        "immunotherapy",
        "advanced",
        "recurrent",
        "ovarian",
        "cancer",
        "immunovaccine",
        "co",
        "plan",
        "add",
        "phase",
        "component",
        "ongoing",
        "phase",
        "1b",
        "study",
        "incyte",
        "epacadostat",
        "low",
        "dose",
        "cyclophosphamide",
        "immunovaccine",
        "phase",
        "arm",
        "study",
        "conducted",
        "amendment",
        "existing",
        "collaboration",
        "immunovaccine",
        "incyte",
        "trial",
        "immunovaccine",
        "inc",
        "expects",
        "provide",
        "clinical",
        "update",
        "phase",
        "1b",
        "program",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}